
There is an increasing number of stories circulating regarding the threat posed by antibiotic-resistant bacteria, only last week four kilometres …

Researchers from the Stark Neurosciences Research Institute at Indiana University have claimed to have finally identified the purpose of an …

NICE has again drawn the ire of a company over its recommendation of its drug, this time round it’s Alexion …

A team from Germany’s RWTH Aachen University, in collaboration with two researchers from Wellcome Genome Campus in the UK, have …

Mylan has agreed to pay $96.5 million in order to settle an antitrust case. The case was related to the …

A recently-adopted initiative by the European Patent Office (EPO) to reduce patient examination times could lead to a stagnation of …

The threat of the Zika virus, though it may have disappeared from the headlines, is still very much present. Any …

Thomas Cueni has become the new Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and will …

Teva has maintained its habit of changing CEOs rather frequently, as Erez Vigodman has left by “mutual agreement”. He becomes …

Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …

Sanofi has reinforced its senior staff with a double-whammy of appointments; firstly, the French firm has announced that it is …

Medherant has brought in Dr Ken Cunningham as Chair in a bid to strengthen the company as it moves into …

Mentor Worldwide, a unit of US pharma firm Johnson & Johnson, has been accused of selling defective breast implants and …

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

As the world’s drug consumption continues to rise alongside advancements in the medical and pharmaceutical industries, so too do new …

Research coming out of The Institute of Cancer Research, and funded by charity Bloodwise, has found that people who inherit …

Lirilumab, Innate Pharma’s acute myeloid leukaemia (AML) treatment, has failed to meet its primary end point in a recent Phase …

A freedom of information request, by Pulse, led to the discovery that 1 in 10 areas in the UK were …

The figures emerging from research conducted by Cancer Research UK predict that rates of cancer in women will rise by …

With World Cancer Day on 4 February, Takeda Oncology’s Liviu Niculescu and Stephen J. Noga talk to Pharmafile.com on the …